Relevances of serum prolactin level to clinical symptoms and disease activity of systemic lupus erythematosis_West China Medical Journal

Authors：

 LIU Xiaoxiao , LIAN Ying

Department of Rheumatism & Immunology, the First People’s Hospital of Chengdu, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

LIU Xiaoxiao, Email: pure_m@163.com

Keywords：

Systemic lupus erythematosus; Disease activity; Systemic lupus erythematosis disease activity index score; Prolactin

DOI：

10.7507/1002-0179.201604263

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the relevances of serum prolactin level to clinical symptoms and disease activities of systemic lupus erythematosis (SLE). Methods From December 2008 to December 2014, 63 female patients who met the American Rheumatism Society diagnostic criteria of SLE in the First People’s Hospital of Chengdu were collected as the SLE group, and other 20 healthy females were collected as the control group. The serum prolactin level was determined by immunofluorescence, and the disease activity of SLE was assessed by SLE Disease Activity Index (SLEDAI). The relevances of serum prolactin level to clinical symptoms and disease activity of SLE patients were analyzed. Results The mean serum prolactin level was (22.35±14.86) ng/mL in the SLE group and (15.30±8.54) ng/mL in the control group, respectively; the difference was statistically significant (P<0.05). In the 63 SLE patients, 15 (23.8%) had higher serum prolactin level compared with the normal ones. According to the SLEDAI score, the SLE patients were divided into stable group (25 patients), mild activity group (21 patients), moderate activity group (10 patients), and severe activity group (7 patients); and their serum prolactin levels were (20.43±11.23), (22.50±13.54), (27.97±21.20), and (33.91±18.18) ng/mL, respectively; the differences were not statistically significant (P>0.05). There were statistically significant differences (P<0.05) between the SLE patients with hyperprolactinemia and the ones with normal serum prolactin level in a number of clinical symptoms such as serositis, kidney damage,hematological system damage, and hypocomplementemia, but the serum prolactin level was not significantly correlated with the SLEDAI (r_s=0.217, P=0.088). Conclusions Less hyperprolactinemia is found in SLE patients. Serum prolactin level is correlated with multiple clinical symptoms and laboratory indexes but not related to disease activity in SLE patients.

Citation： LIU Xiaoxiao, LIAN Ying. Relevances of serum prolactin level to clinical symptoms and disease activity of systemic lupus erythematosis. West China Medical Journal, 2017, 32(12): 1863-1866. doi: 10.7507/1002-0179.201604263 Copy

1.	Chikanza IC. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci, 1999, 876(1): 119-130.
2.	Massimo C, Nadine B, Lawrence S, et al. Prolactin: a versatile regulator of inflammation and autoimmune pathology. Autoimmun Rev, 2015, 14(3): 223-230.
3.	Ana L, Pereira S, Gonzalo LR, et al. Prolactin in inflammatory response. Adv Exp Med Biol, 2015(846): 243-264.
4.	李圣楠, 黄慈波. 系统性红斑狼疮的诊断治疗进展. 临床药物治疗杂志, 2010, 8(1): 6-10.
5.	Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35(6): 630-640.
6.	Jara LJ, Medina G, Saavedra MA, et al. Prolactin and autoimmunity. Clin Rev Allergy Immunol, 2011, 40(1): 50-59.
7.	Peeva E, Venkatesh J, Michael D, et al. Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother, 2004, 58(5): 310-319.
8.	Larrea F, Martínez-Castillo A, Cabrera V, et al. A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus. J Clin Endocrinol Metab, 1997, 82(11): 3664-3669.
9.	Košir Pogačnik R, Meden Vrtovec H, Vizjak A, et al. Possible role of autoimmunity in patients with premature ovarian insufficiency. Int J Fertil Steril, 2014, 7(4): 281-290.
10.	McMurray R, Keisler D, Walker S. Bromocriptine decreases early mortality in female NZB/W mice. Arthritis Rheum, 1990, 33(9 Suppl): 103.
11.	Jara LJ, Cruz-Cruz P, Saavedra MA, et al. Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. Ann N Y Acad Sci, 2007, 1110(1): 297-304.
12.	Ugartegil MF, Gamboacardenas RV, Diazdeza K, et al. High prolactin levels are independently associated with damage accrual in systemic lupus erythematosus patients. Lupus, 2014, 23(10): 969-974.
13.	Méndez I, Alcocer-Varela J, Parra A, et al. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin. Lupus, 2004, 13(1): 45-53.
14.	Lavalle C, Loyo E, Paniagua R, et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol, 1987, 14(2): 268-272.
15.	Cárdenasmondragón G, Ulloaaguirre A, Isordiasalas I, et al. Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. J Rheumatol, 2007, 34(7): 1514-1521.
16.	Haghighi A, Lahmi F. Hyperprolactinemia in patients with systemic lupus erythematosus: correlation with disease activity. Aplar J Rheumatol, 2010, 9(3): 227-231.
17.	Mcmurray RW, Weidensaul D, Allen SH, et al. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol, 1995, 22(11): 2084-2091.
18.	Karimifar M, Tahmasebi A, Bonakdar ZS, et al. Correlation of serum prolactin levels and disease activity in systematic lupus erythematosus. Rheumatol Int, 2013, 33(2): 511-516.
19.	Leaños-Miranda A, Chávez-Rueda KA, Blanco-Favela F. Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum, 2001, 44(4): 866-875.
20.	Leanos A, Pascoe D, Fraga A, et al. Antiprolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus, 1998, 7(6): 398-403.

1. Chikanza IC. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci, 1999, 876(1): 119-130.
2. Massimo C, Nadine B, Lawrence S, et al. Prolactin: a versatile regulator of inflammation and autoimmune pathology. Autoimmun Rev, 2015, 14(3): 223-230.
3. Ana L, Pereira S, Gonzalo LR, et al. Prolactin in inflammatory response. Adv Exp Med Biol, 2015(846): 243-264.
4. 李圣楠, 黄慈波. 系统性红斑狼疮的诊断治疗进展. 临床药物治疗杂志, 2010, 8(1): 6-10.
5. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35(6): 630-640.
6. Jara LJ, Medina G, Saavedra MA, et al. Prolactin and autoimmunity. Clin Rev Allergy Immunol, 2011, 40(1): 50-59.
7. Peeva E, Venkatesh J, Michael D, et al. Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother, 2004, 58(5): 310-319.
8. Larrea F, Martínez-Castillo A, Cabrera V, et al. A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus. J Clin Endocrinol Metab, 1997, 82(11): 3664-3669.
9. Košir Pogačnik R, Meden Vrtovec H, Vizjak A, et al. Possible role of autoimmunity in patients with premature ovarian insufficiency. Int J Fertil Steril, 2014, 7(4): 281-290.
10. McMurray R, Keisler D, Walker S. Bromocriptine decreases early mortality in female NZB/W mice. Arthritis Rheum, 1990, 33(9 Suppl): 103.
11. Jara LJ, Cruz-Cruz P, Saavedra MA, et al. Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. Ann N Y Acad Sci, 2007, 1110(1): 297-304.
12. Ugartegil MF, Gamboacardenas RV, Diazdeza K, et al. High prolactin levels are independently associated with damage accrual in systemic lupus erythematosus patients. Lupus, 2014, 23(10): 969-974.
13. Méndez I, Alcocer-Varela J, Parra A, et al. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin. Lupus, 2004, 13(1): 45-53.
14. Lavalle C, Loyo E, Paniagua R, et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol, 1987, 14(2): 268-272.
15. Cárdenasmondragón G, Ulloaaguirre A, Isordiasalas I, et al. Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. J Rheumatol, 2007, 34(7): 1514-1521.
16. Haghighi A, Lahmi F. Hyperprolactinemia in patients with systemic lupus erythematosus: correlation with disease activity. Aplar J Rheumatol, 2010, 9(3): 227-231.
17. Mcmurray RW, Weidensaul D, Allen SH, et al. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol, 1995, 22(11): 2084-2091.
18. Karimifar M, Tahmasebi A, Bonakdar ZS, et al. Correlation of serum prolactin levels and disease activity in systematic lupus erythematosus. Rheumatol Int, 2013, 33(2): 511-516.
19. Leaños-Miranda A, Chávez-Rueda KA, Blanco-Favela F. Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum, 2001, 44(4): 866-875.
20. Leanos A, Pascoe D, Fraga A, et al. Antiprolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus, 1998, 7(6): 398-403.

West China Medical Journal

Relevances of serum prolactin level to clinical symptoms and disease activity of systemic lupus erythematosis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content